MY180829A - A mixed fatty acids formulation for enhancing mangostin anticancer effect - Google Patents

A mixed fatty acids formulation for enhancing mangostin anticancer effect

Info

Publication number
MY180829A
MY180829A MYPI2015701122A MYPI2015701122A MY180829A MY 180829 A MY180829 A MY 180829A MY PI2015701122 A MYPI2015701122 A MY PI2015701122A MY PI2015701122 A MYPI2015701122 A MY PI2015701122A MY 180829 A MY180829 A MY 180829A
Authority
MY
Malaysia
Prior art keywords
mangostin
lipid nanoparticles
compounds
enhancing
fatty acids
Prior art date
Application number
MYPI2015701122A
Inventor
Dr Misni Bin Misran Prof
Najihah Binti Mohd Hashim Dr
Juin Onn Woo
Shu Xian Tiew
Original Assignee
Univ Malaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Malaya filed Critical Univ Malaya
Priority to MYPI2015701122A priority Critical patent/MY180829A/en
Publication of MY180829A publication Critical patent/MY180829A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention disclosed a lipid nanoparticles carrier formulation to encapsulate mangostin compounds for better anticancer property. The lipid nanoparticles carrier formulation consists of 50 to 80 wt% of stearic acid and 20 to 50 wt% of oleic acid as the raw material of lipid nanoparticles to encapsulate the mangostin compounds and 0.25 to 2.0 wt% non-ionic surfactant to stabilize the lipid nanoparticles. In a specific embodiment, the mangostin compounds can be generally represented by Molecular Formula (1) or its pharmaceutical acceptable salts, prodrug and solvates thereof. Besides, the present invention also disclosed mangostin compounds loaded lipid nanoparticles and a method of making the same. Molecular Formula (1)
MYPI2015701122A 2015-04-09 2015-04-09 A mixed fatty acids formulation for enhancing mangostin anticancer effect MY180829A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2015701122A MY180829A (en) 2015-04-09 2015-04-09 A mixed fatty acids formulation for enhancing mangostin anticancer effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2015701122A MY180829A (en) 2015-04-09 2015-04-09 A mixed fatty acids formulation for enhancing mangostin anticancer effect

Publications (1)

Publication Number Publication Date
MY180829A true MY180829A (en) 2020-12-10

Family

ID=79624161

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015701122A MY180829A (en) 2015-04-09 2015-04-09 A mixed fatty acids formulation for enhancing mangostin anticancer effect

Country Status (1)

Country Link
MY (1) MY180829A (en)

Similar Documents

Publication Publication Date Title
MX2024008101A (en) Lipid nanoparticle formulations for crispr/cas components.
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2018015709A (en) Azabenzimidazole derivatives as pi3k beta inhibitors.
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
NZ747847A (en) Lipid compositions
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12018500852A1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
SG10201907289VA (en) Monomethylfumarate prodrug compositions
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12018501292A1 (en) Pharmaceutical compositions comprising phenylaminopyridine derviative
MX2017016231A (en) Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors.
PH12019500822A1 (en) Crystalline forms of eravacycline
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
MX2015012771A (en) Method of treating vitamin b12 deficiency.
MY180829A (en) A mixed fatty acids formulation for enhancing mangostin anticancer effect
MX2017008076A (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors.
EP2594268A4 (en) Anti-angiogenic composition containing macrolactin a and a derivative thereof as active ingredients
MX2018015269A (en) Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof.
NZ702684A (en) Hexadepsipeptide analogues as anticancer compounds
MX2018005134A (en) Fviii formulation.